Quick Comparison
| Noopept | Omega-3 (DHA) | |
|---|---|---|
| Half-Life | 30-60 minutes (active metabolite cycloprolylglycine persists longer) | 20-67 hours (plasma), but brain DHA turns over slowly over weeks |
| Typical Dosage | Standard: 10-30 mg sublingually or orally, 2-3 times daily. Sublingual administration provides faster onset. Do not exceed 30 mg per dose. | Standard: 1-2 g combined EPA/DHA daily (aim for at least 500 mg DHA). For depression: 1-2 g EPA-dominant fish oil. Triglyceride form is better absorbed than ethyl ester. Take with a fatty meal. |
| Administration | Oral or sublingual (sublingual preferred for faster onset and higher bioavailability). Available as powder, capsules, or sublingual tablets. | Oral (softgels, liquid). Triglyceride or phospholipid forms preferred over ethyl ester for bioavailability. Take with food containing fat. |
| Research Papers | 10 papers | 10 papers |
| Categories |
Mechanism of Action
Noopept
Noopept modulates AMPA and NMDA receptors similarly to racetams through positive allosteric modulation. Its key distinguishing feature is upregulation of BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) via activation of TrkB and TrkA receptor signaling cascades — these neurotrophins are essential for neuronal growth, survival, dendritic arborization, and synaptic plasticity. Noopept inhibits glutamate-induced excitotoxicity by reducing calcium influx through NMDA receptors and modulating the NR2B subunit. It activates the PI3K/Akt and MAPK/ERK pathways downstream of neurotrophin receptors. The active metabolite cycloprolylglycine (a cyclic dipeptide) has endogenous nootropic activity, potentially acting as a trace amine-associated receptor ligand. Neuroprotection is further mediated through antioxidant effects and mitochondrial stabilization.
Omega-3 (DHA)
DHA is a structural component of neuronal phospholipids (particularly phosphatidylethanolamine and phosphatidylserine in synaptic membranes), maintaining membrane fluidity which is essential for G-protein-coupled receptor function, ion channel gating, and synaptic vesicle fusion. DHA is metabolized by 15-lipoxygenase to specialized pro-resolving mediators (SPMs) including neuroprotectin D1 (NPD1), which actively resolve neuroinflammation by reducing NF-kappaB activation and pro-inflammatory cytokine production. DHA supports BDNF expression through modulation of the CREB pathway and promotes synaptic plasticity by enhancing long-term potentiation (LTP) and dendritic spine density. It also influences neurotransmitter receptor conformation and binding efficiency. Deficiency impairs membrane signaling, increases neuroinflammation, and accelerates cognitive decline.
Risks & Safety
Noopept
Common
Headache (especially without choline supplementation), irritability at higher doses, brain fog in some users.
Serious
No serious adverse effects documented.
Rare
Emotional blunting at high doses, insomnia, allergic reactions.
Omega-3 (DHA)
Common
Fishy aftertaste, burping, mild gastrointestinal discomfort.
Serious
High doses (>3 g/day) may increase bleeding risk — caution with blood thinners. Fish oil quality matters — choose products tested for mercury and oxidation.
Rare
Allergic reaction in people with fish/shellfish allergy.
Full Profiles
Noopept →
A synthetic peptide-derived nootropic often grouped with racetams due to similar effects, though it is technically a dipeptide analog of piracetam. Roughly 1000x more potent by weight than piracetam, requiring only 10-30 mg per dose. It provides both immediate cognitive enhancement and long-term neuroprotective benefits through BDNF and NGF upregulation.
Omega-3 (DHA) →
DHA (docosahexaenoic acid) makes up approximately 40% of the polyunsaturated fatty acids in the brain and is essential for neuronal membrane structure, fluidity, and signaling. DHA deficiency is associated with cognitive decline, depression, and neuroinflammation. It is one of the few supplements with strong evidence for maintaining brain health across the lifespan.